Video interview with CEO Young15 Feb 2016 14:17
http://tinyurl.com/h7g4rnn
E-Therapeutics (LON:ETX) chief executive Malcolm Young tells Proactive that the firm has hit the “sweet spot” on the drug candidate ETS6103 following its latest test results.
The Phase IIb study, which was a larger study at a lower dose showed the drug was a little bit off the efficacy of its rival amitriptyline, but was still effective.
But the firm has previously completed a Phase IIa study on ETS6103, which was carried out on a small number of patients at a higher dose, showing the drug had the same efficacy as its closest rival.
Young says that the drug has a “cleaner profile” than amitriptyline, and adds that “across the two studies, we are pleased.”